Stada group
Germany's STADA Group, which the Hemofarm of Vrsac operates within, reported on Aug. 26 that in the first half of the year the company recorded a 16-percent rise in sales to EUR1.47 billion, alongside "organic growth of nine percent."
The German company went on to say that it was a broad and diverse spectrum of drugs and medicaments that made possible the jump, despite the predicaments of the pandemic that had cut growth rates in the pharmaceutical sector as well.
A considerable decrease was reported in the second quarter in the states where patients cover directly the cost of their medical treatment. STADA Director General Peter Goldschmidt said that "strong commitment and entrepreneurial spirit" were behind the success of his company.
To get full access to all content of interest see our
Subscription offer
Or
Register for free
And read up to 5 articles each month.
Already have an account? Please Log in.